Notch ligation by Delta1 inhibits peripheral immune responses to transplantation antigens by a CD8⁺ cell–dependent mechanism by Wong, Kenneth K. et al.
The Journal of Clinical Investigation | December 2003 | Volume 112 | Number 11 1741
receptors (Notch1–4) and five ligands of the Delta-like
families (Delta-like 1 [Dl1], Dl3, Dl4) and Jagged fam-
ilies (Jagged1, Jagged2). The precise functions of these
alternate families of ligands, and in particular whether
they have redundant activities, is not completely under-
stood. Recent studies, however, have indicated that
during lymphoid differentiation, signaling through
Delta-like proteins inhibits B cell differentiation (2),
while that through Jagged proteins allows it. Further-
more, while the activity of Delta is potentiated by the
Notch modifier, Fringe, the activity of Jagged is inhib-
ited (3). As well as lateral specification and inductive
signaling, Notch can affect cell fate through influenc-
ing apoptosis or cell cycle arrest (4–6). Taken together,
these findings suggest that Notch signaling may act as
a “gatekeeper” in controlling cell fate choices by influ-
encing proliferation, differentiation, and death.
A number of studies have implicated Notch signaling
in hematopoiesis, T-B lineage commitment, and
thymic T cell development (4, 7–13; for review see refs.
14–16). There are also a number of studies that suggest
a role for Notch signaling in differentiation and regu-
lation of the mature peripheral immune system. First,
APCs retrovirally transduced to constitutively express
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Notch signaling plays a fundamental role in determining the outcome of differentiation processes
in many tissues. Notch signaling has been implicated in T versus B cell lineage commitment, thymic
differentiation, and bone marrow hematopoietic precursor renewal and differentiation. Notch recep-
tors and their ligands are also expressed on the surface of mature lymphocytes and APCs, but the
effects of Notch signaling in the peripheral immune system remain poorly defined. The aim of the
studies reported here was to investigate the effects of signaling through the Notch receptor using a
ligand of the Delta-like family. We show that Notch ligation in the mature immune system marked-
ly decreases responses to transplantation antigens. Constitutive expression of Delta-like 1 on alloanti-
gen-bearing cells renders them nonimmunogenic and able to induce specific unresponsiveness to a
challenge with the same alloantigen, even in the form of a cardiac allograft. These effects could be
reversed by depletion of CD8+ cells at the time of transplantation. Ligation of Notch on splenic CD8+
cells results in a dramatic decrease in IFN-γ with a concomitant enhancement of IL-10 production,
suggesting that Notch signaling can alter the differentiation potential of CD8+ cells. These data impli-
cate Notch signaling in regulation of peripheral immunity and suggest a novel approach for manip-
ulating deleterious immune responses.
J. Clin. Invest. 112:1741–1750 (2003). doi:10.1172/JCI200318020.
Introduction
The Notch-signaling pathway plays an integral role in
cell fate decisions in all organisms, mutations in the
Notch receptor, or its ligands, resulting in develop-
mental abnormalities and embryonic lethality (1). Sig-
naling through the cell surface receptor, Notch is acti-
vated by ligation to DSL (from: Delta, Serrate, and Lag
proteins). In vertebrates there are four identified Notch
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the Notch ligand, Jagged-1, can induce peripheral tol-
erance to the house dust mite antigen Der p 1 (17). Sec-
ond, the Notch ligand Dl1 can inhibit the differentia-
tion of monocytes into macrophages, but allows their
differentiation into DCs (18). Finally, in elegant stud-
ies involving conditional inactivation of the Notch
pathway transcription factor, RBP-j, Tanigaki et al. (19)
demonstrated that Notch signaling regulates the line-
age commitment of mature peripheral B cells. As yet,
however, there are no data addressing the activities of
ligands of the Delta-like family on T cells nor the
effects of Notch signaling on CD8+ cells. The aim of the
studies reported here was to investigate the effects and
mechanisms of action of Delta-mediated ligation of
Notch on peripheral T cell–dependent immunity to
transplantation antigens.
Methods
Production and characterization of Notch ligand transfectants.
L cells express endogenous MHC class I antigens of the
H-2k haplotype, but no endogenous MHC class II anti-
gens. Kb and Ab (20) are L cells transfected with MHC
class I (h-2Kb) or MHC class II (h-2Ab), respectively, of
the H-2b haplotype (kindly provided by K. Wood, Uni-
versity of Oxford, Oxford, United Kingdom). Mouse
Dl1 cDNA was subcloned into the mammalian expres-
sion vector, pIRES2/enhanced GFP (EGFP) (BD Bio-
sciences Clontech UK, Cowley, United Kingdom) for
transfection into L cells using Effectene (Qiagen Ltd.,
Crawley, United Kingdom). Stable transfectants were
selected in G418 (Life Technologies Ltd., Paisley, Unit-
ed Kingdom) and twice sorted using flow cytometry to
produce a population of EGFP-expressing cells named
Kb/Dl1 and Ab/Dl1. Control Kb and Ab transfected with
empty pIRES/EGFP were similarly selected and shown
to behave in the same way as the Kb and Ab cells in
popliteal lymph node (PLN) assays.
Ab’s. Biotinylated AF6-88 (anti–H-2Kb) and 1D9
(anti–H-2Ab) were provided by A. Livingstone (Univer-
sity of Rochester Medical Center, Rochester, New York,
USA). Anti-CD3 (FITC conjugated), streptavidin-phy-
coerythrin, and annexin V staining kits were from
PharMingen (Cowley, United Kingdom). Depleting
CD8 (YTS169) and CD4 (YTS191) Ab’s were a kind gift
of S. Cobbold (University of Oxford, Oxford, United
Kingdom) (21). Rat Ig was from Sigma-Aldrich Co. Ltd.
(Gillingham, United Kingdom).
Flow cytometry. Viable cells (105) were aliquoted into wells
of a 96-well plate (Bibby Sterilin Ltd., Stone, United King-
dom) and incubated with titrated amounts of primary
Ab’s in 50 µl PBS/FCS. After washing, cells were resus-
pended with secondary Ab. Stained cells were analyzed
using a FACscan II flow cytometer with Cellquest software
(Becton-Dickinson UK Ltd., Oxford, United Kingdom).
Quantitative RT-PCR. Total RNA was extracted using
StrataPrep (Stratagene Europe, Amsterdam, The
Netherlands) or Qiagen RNeasy kits (Qiagen Ltd.).
Total RNA (400–500 ng) was used for cDNA synthesis
using a multi-cDNA kit and random oligonucleotide
primers (according to the manufacturer’s instructions;
ABI, Warrington, United Kingdom) or Superscript II
(Invitrogen, Paisley, United Kingdom) and oligo-dT+
random decamers (Ambion Europe Ltd., Huntingdon,
United Kingdom). Samples were resuspended in 100 µl
final volme with distilled water, and 2.5 µl of this was
used per well in a final volume of 25 µl for PCR. Primer
and probe sequences were as follows: Mouse notch1: 
forward, TCCAGAGTGCCACCGATGT; reverse, TCCACCG-
GCTCACTCTTCAC; probe, CTGCCTTCCTAGGTGCTC-
TTGCGTCA; Mouse notch2: forward, ACCCTCCGCCGA-
GACTCT; reverse, TCCCAGAACCAATCAGGTTAGC; probe,
CCTGTCCCACAGGTTCACGGCG; Mouse notch4: forward,
TGTCTCCCCCATAGAGTATGCA; reverse, CTCGAAAT-
CAACTTTGTCCTCTTG; probe, CCGGACATCCTAAACC-
CTCCCATTG; Mouse dl3: forward, GGCGGTGAAGATC-
CTGACTCT; reverse, CGGTCCACCCTCTTCTCACA; probe,
ATTGCCCACCTGGTTTCCAAGGCTC; Mouse dl1: forward,
TCCTTTCGCGTATGCCTCAA; reverse, CATCAGGCAG-
GCTGAAGGA; probe, ACTACCAGGCCAGCGTGTCACCG;
Mouse jagged1: forward, CCCGCACCCAGGAGTTGT;
reverse, CACCCCAGTTGGTCTCACAGA; probe, CACCTG-
CAATGAACCCTGGCAGTG; Mouse jagged2: forward,
CAGCTGGACGCCAATGAGT; reverse, GCCAATCAGGTT-
TTTGCAAGA; probe, AGCATTAAGGCACGGCTTCCCT-
TCA; Mouse Hes1: forward, GGTGCTGATAACAGCGGAAT;
reverse, CCATCCAATCGGTAGTAGCG; 18s: forward,
GTAACCCGTTGAACCCCATT; reverse, CCATCCAATCG-
GTAGTAGCG; or off the shelfprimers from ABI. All
primers were purchased from ABI.
All probes were labeled with 5′-6-carboxyfluoroscein
and 3′-6-carboxytetramethylrhodamin. The Hes1
amplicon was detected with SYBR green.
Samples were run on an ABI 7700 sequence detection
system or a Lightcycler (Roche Diagnostics Ltd., Lewes,
United Kingdom). Relative quantification of mRNA
levels was performed using the comparative cycle
threshold (CT) method, following the manufacturer’s
instructions (ABI).
Notch-signaling reporter assay. CHO cells were stably
transfected with a full-length cDNA encoding human
Notch2, which was isolated from a commercially avail-
able cDNA bank (OriGen Technologies Inc., Rockville,
Maryland, USA). These cells were further transfected
with a construct containing a multimerized (10 times)
CBF1 response element upstream of a luciferase cDNA.
Stable transfectants (CHO/N2-luc, 2 × 104cells/well)
were placed into white 96-well OptiPlates (Canberra
Packard Ltd., Pangbourne, United Kingdom) and
allowed to adhere for 1 hour at 37°C before adding the
L cell transfectants or control untransfected CHO cells
at 2 × 105/well in medium containing 10 mM LiCl. L
cells and control untransfected CHO cells were mito-
mycin C treated (100 µg/ml, 70 minutes, 37°C) before
they were added to the assay. Cultures were incubated
at 37°C for 24 hours. Supernatants were removed from
wells, and cells were washed and lysed by the addition
of 100 µl of Glo lysis buffer (Promega UK Ltd.,
Southampton, United Kingdom). After 5 minutes at
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room temperature, 100 µl of SteadyGlo luciferase assay
reagent (Promega UK Ltd.) was added, and the lumines-
cence was read in a TopCount (Canberra Packard Ltd.).
Mice. C57BL/10 (H-2b), BALB/c (H-2d), and C3H/HeJ
(H-2k) mice between 8 and 12 weeks old were obtained
from Harlan Olac Ltd. (Bicester, United Kingdom) and
kept in the animal facilities in Central Biomedical Ser-
vices at Imperial College in accordance with Home
Office guidelines [Animals (Scientific Procedures) Act
1986]. The mice were used in both PLN assays and heart
transplantation experiments. C57BL/10 mice were used
as allogeneic donors, BALB/c mice were used as third-
party donors, and C3H/HeJ mice were used as recipients.
Heterotopic heart transplantation. Heterotopic heart
transplants were performed as described by Corry (22).
Animals were injected with cells 14 days before trans-
plantation, as indicated. Doses of cells were based on
those used previously (20). Injections were as follows:
Kb, 2.5 × 106 or 5 × 106; Ab, 1 × 106; Kb/Dl1, 2.5 × 106 or
5 × 106; Ab/Dl1, 1 × 106; Kb, 5 × 106, + Ab, 1 × 106; and
Kb/Dl1, 5 × 106, plus Ab/Dl1, 1 × 106. Doses of 2.5 × 106
or 5 × 106 Kb/Dl1 were compared with 2.5 × 106 or 5 × 106
Kb due to the sharp dose-response curve reported pre-
viously regarding the effect of Kb in transplantation
experiments (20). Both doses of both cells had the same
effect on graft survival, and, consequently, doses of 
5 × 106 Kb or Kb/Dl1 cells were given in all mixing exper-
iments. Where shown, animals were treated with 1 mg
YTS169, YTS191, or rat IgG intraperitoneally on day 1
and day 0.
PLN assay. Cells (106) in 15 µl of PBS were injected sub-
cutaneously into the left foot pad (LFP). The ratio of Kb-
expressing to Ab-expressing cells used in a mixed popu-
lation was 5:1, as above. Allogeneic lymph node cells
(LNCs) were irradiated with 30 Gy before use. Chal-
lenges were with 1 × 106 cells or 0.6 × 106 DCs. PLNs
were harvested, dissected free of fat and surrounding tis-
sue, and weighed (at 7 days), or made into a single cell
suspension (at times shown). Results are expressed as
mean weight or cell number ratio of left PLN to right
PLN (LPLN/RPLN) ± SEM. A LPLN/RPLN ratio of 1
equates to no response.
Bone marrow–derived DCs. Bone marrow cells were har-
vested, red cells lysed, and the remaining cells were cul-
tured at a concentration of 2 × 106 cells/ml in RPMI-1640
plus 10% FCS plus antibiotics (GibcoBRL; Life Tech-
nologies Ltd.) with GM-CSF and IL-4 (10 ng/ml each;
PeproTech EC Ltd., Northampton, United Kingdom).
Two milliliters of the medium was replaced on days 2 and
4. DCs were used on day 7.
Indirect allopresentation. Seven day–cultured DCs were
treated with mitomycin C (Sigma-Aldrich Co. Ltd.) at 50
µg/ml for 1 hour at 37°C. Cells were washed three times
and incubated overnight in serum-free RPMI-1640 to
induce apoptosis. These were fed to growing DCs on
days 3 to 5 of their culture. On day 7, DCs that had been
fed with apoptotic DCs were used in PLN assays.
Dl1-Fc cultures. Ninety-six– or 24-well plates were coat-
ed with anti-hamster IgG1 and anti-human IgG4 cap-
ture Ab’s at 1 µg/ml in PBS. Plates were incubated
overnight at 4°C and washed three times with PBS
before addition of hamster anti-mouse CD3 (clone
145.2C11, concentrations as shown) and Dl1-Fc (various
concentrations as shown). Dl1-Fc protein was purified
from stably transfected CHO cell supernatants and was
shown to be active in a Notch-signaling assay (23). Plates
were then incubated for 2 hours at 37°C and washed
three times with PBS. CD4+ or CD8+ cells were positive-
ly selected from red cell lysed spleen cell suspensions
using Miltenyti microbeads according to the manufac-
turer’s instructions. For cytokine analysis in 96-well
plates, 2 × 105 to 3 × 105 cells/well were added to treated
plates with soluble anti-CD28 at 2 µg/ml. For RT-PCR
in 24-well plates, 2.5 × 106 cells/well were added. Coating
and activating Ab’s were from PharMingen. Cells were
incubated for 5 days before removal of supernatants for
cytokine analysis by ELISA using Ab pairs from R&D
Systems Europe Ltd. (Oxon, United Kingdom) or for 4
hours before collection for RNA preparation.
Statistical analysis. Statistics were performed using Mann-
Whitney test (PLN assay) or Wilcoxon’s log-rank test
(transplants) with Bonferroni correction as appropriate.
Results
Characterization of L cells. L cells express endogenous
MHC class I antigens of the H-2k haplotype, but no
endogenous MHC class II antigens. Kb and Ab are L
cells transfected with allogeneic MHC class I or MHC
class II, respectively, of the H-2b haplotype (20). Kb and
Ab cells were further transfected with a mouse
Dl1/EGFP bicistronic cDNA. We chose to use a Notch
ligand of the Delta-like family because the effects of
this ligand family have not been studied previously in
the context of T cell–dependent peripheral immunity.
Following selection, the Notch ligand transfectants
were sorted into EGFP-expressing populations (MHC
class I–expressing Dl1 transfectants were termed
Kb/Dl1, and MHC class II–expressing Dl1 transfectants
were termed Ab/Dl1) and analyzed by flow cytometry
(Figure 1a). The initial flow-cytometric analysis of
EGFP expression indicated that higher expression of
Dl1 would be found in Kb/Dl1 than in Ab/Dl1 cells, and
this was confirmed at the transcript level using quanti-
tative (Taqman) RT-PCR (Figure 1b). Furthermore, Dl1
transcripts were undetectable in the parental Kb and Ab
cells. By flow cytometry, Dl1 transfectants were shown
to express the same levels of H-2b MHC proteins as
their parental counterparts (Figure 1c).
Notch signaling can be induced by Dl1-mediated ligation in
both reporter assays and in T cells. A reporter assay system
was used to determine the ability of Dl1 transfectants
and their parental counterparts to actively signal
through the Notch receptor. Notch2-expressing CHO
cells were transfected with a plasmid construct that
reports Notch pathway activation by expression of
luciferase. Such cells were then cocultured with the var-
ious L cell transfectants and assayed for luciferase activ-
ity. The Dl1 protein, introduced by transfection into
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both Ab/Dl1 and Kb/Dl1, was shown to be functionally
active in this reporter assay for Notch ligand activity,
but as predicted by RT-PCR, the level of reporter activa-
tion by the Ab/Dl1 transfectants was found to be lower
than that by the Kb/Dl1 cells (Figure 2a). Importantly,
no signaling was observed when Kb or Ab cells were
introduced into the assay, suggesting that there is no, or
insignificant, endogenous Notch ligand expressed by
these cells. The expression of endogenous ligands was
further explored by using quantitative RT-PCR. Of the
Notch ligands, only low levels of Jagged2 were detected
in all L cells at similar levels, although all cells did
express significant levels of both Notch1 and Notch2
(Figure 2b). It is known that transendocytosis of the
Notch receptor by ligand-expressing cells can affect the
ability of that cell to signal or to express other ligands.
In our experiments, however, the Dl1–transfected cells
signaled well and did not have upregulated expression
of alternative ligands. Taken together, these findings
indicate that the effects observed in functional assays
were due solely to the expression of Dl1 introduced into
these cells by transfection.
We also wished to know whether Notch signaling
could be directly activated in T cells. To explore this, T
cells stimulated in the presence or absence of Notch lig-
and were assessed for increased transcript levels of Hes1.
Figure 1
Characterization of L cell transfectants. (a) MHC class I and II (Kb
and Ab, respectively) and MHC Dl1-transfected (Kb/Dl1 and Ab/Dl1)
cells were analyzed using flow cytometry. EGFP expression is shown
on FL1-H and indicates the level of expression of the transfected
Dl1:EGFP bicistronic construct. EGFP expression reflects Dl1 expres-
sion. FL1-H, level of green fluorescence. (b) Quantitative RT-PCR for
Dl1 transcripts in parental Kb and Ab cells and their Dl1-transfected
counterparts. All samples were normalized by assessment of 18s
RNA. Mouse embryonic RNA (day 11) was used as a positive control
in the experiment, and transcript levels in other samples are expressed
relative to this. (c) Flow-cytometric analysis of MHC class I (H-2Kb,
left panels) and MHC class II (H-2Ab, right panels) expression on all
cell lines using biotinylated AF6-88 (MHC class I) and 1D9 (MHC
class II) mAb’s (filled traces) or no first-stage Ab (open traces). All
data are representative of at least three repeat experiments. FL2-H,
level of red fluorescence.
Figure 2
Dl1 is able to activate Notch signaling in reporter cell assays and in
T cells. (a) CHO/N2-luc cells, which contain a construct that reports
Notch pathway activation by expression of luciferase, were cultured
with mitomycin C–treated Kb, Kb/Dl1, Ab, or Ab/Dl1. Untransfected
CHO cells were used to control cell numbers in the assay and do not
activate the Notch pathway in CHO/N2-luc cells. Cell lysates were
assayed for luciferase activity after 24 hours. (b) Quantitative 
RT-PCR was used to assess the expression of Notch receptors and
Notch ligands by L cells. All samples were normalized by assessment
amplification of 18s RNA. Mouse embryonic RNA (day 11) was used
as a positive control in the experiment, and transcript levels in other
samples are expressed relative to this. (c) Positively selected CD4+ or
CD8+ cells were cultured in the presence of immobilized CD3 Ab
(0.12 µg/ml), CD28 Ab (2 µg/ml), and immobilized Dl1-Fc fusion
protein (40 µg/ml). After 4 hours, cells were harvested and RNA
extracted. Samples were analyzed for Hes1 transcripts and normal-
ized using 18s amplification by quantitative RT-PCR. Data are
expressed as fold induction compared with cells incubated with CD3
and CD28 Ab’s in the absence of Dl1-Fc fusion protein. All data are
representative of at least three repeat experiments.
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Hes1 is a downstream target of Notch signaling, and an
increase in transcripts of this gene indicates active
Notch signaling in cells, including those of the
hematopoietic system (2, 24, 25). Preliminary experi-
ments using L cell stimulators indicated that, indeed,
the Dl1 transfectants, but not their parental counter-
parts, could deliver a signal through Notch as assessed
by increased expression of Hes1 (data not shown). We
were concerned, however, that because the Dl1 trans-
fectants expressed high levels of Hes1 (data not shown),
small contamination with these cells could bias our
results. We therefore used a Dl1-Fc fusion protein to
stimulate Notch signaling in T cells stimulated with
CD3 and CD28 Ab’s. These experiments showed that
Dl1-mediated ligation of Notch is able to induce upreg-
ulated transcript levels of Hes1 in both CD4+ and CD8+
cells, thereby indicating that Notch signaling can be
directly activated in T cells (Figure 2c).
Dl1-transfected L cells are not immunogenic and can induce
antigen-specific unresponsiveness. The immunogenicity
and ability to regulate immune responses of the L cells
was first assessed using a system of local antigen chal-
lenge, the PLN assay. In this assay animals are chal-
lenged in the footpad with antigen, and responses are
measured in the draining PLN. In PLN assays, neither
Ab/Dl1 nor Kb/Dl1 were immunogenic. Moreover,
these Notch ligand transfectants were capable respec-
tively of inducing unresponsiveness to a subsequent
challenge with Ab (Figure 3a) or Kb (data not shown)
cells not expressing the Notch ligand. By contrast, Ab
and Kb cells were immunogenic and could prime the
animals to a subsequent challenge with Ab (Figure 3a)
or Kb (data not shown), respectively. Neither Ab/Dl1
nor Kb/Dl1 alone could induce unresponsiveness to a
subsequent challenge with H-2b LNCs that express the
entire H-2b haplotype (H-2b; Figure 3a), but mixtures of
Ab/Dl1 and Kb/Dl1 could do so (Figure 3b). The unre-
sponsiveness induced by pretreatment with Ab/Dl1 and
Kb/Dl1 was antigen specific in that third-party respons-
es to LNCs of H-2d origin were unaltered (Figure 3c).
Unresponsiveness is not induced to MHC antigens presented
through the indirect pathway. Transplantation antigens
can be presented either directly, that is on cells express-
ing the alloantigen, or indirectly, that is as processed
peptides on self APCs. Both pathways have been shown
to be important in evoking acute graft rejection
(26–28). The experiments described above indicated
that T cells recognizing alloantigen directly on the
expressing cell were inhibited by the pretreatment pro-
tocol, and this was confirmed in PLN assays where the
APCs used in challenge were DCs rather than LNCs
(direct; Figure 3d). To test responses of T cells recog-
nizing the alloantigen indirectly, we took DCs of H-2k
origin and fed them with mitomycin C–treated DCs of
H-2b origin. The fed DCs are able to present peptides of
H-2b origin in the context of H-2k MHC, that is indi-
rectly, and are able to stimulate a good PLN response
in H-2k mice whether animals were pretreated with Kb
plus Ab or Kb/Dl1 plus Ab/Dl1 (indirect; Figure 3d).
These data show that while pretreatment with Kb/Dl1
plus Ab/Dl1 inhibits responses stimulated by directly
presented alloantigen, it does not affect responses to
indirectly presented antigen. Pretreatment with Kb plus
Ab cells is unable to inhibit responses to alloantigen
presented either directly or indirectly.
Kinetics and apoptosis in PLN responses. To follow more
closely events in Kb/Dl1 plus Ab/Dl1–pretreated ani-
mals following antigen challenge, PLNs were removed
at various times and total or T cell numbers counted
and expressed as a ratio of injected to noninjected sides
(total cells, Figure 4a; T cells, Figure 4b). The response
in animals pretreated with Kb plus Ab was clearly
primed, with cell numbers rising rapidly in the first
18–48 hours and remaining elevated during the entire
time course. Animals pretreated with Kb/Dl1 plus
Figure 3
Notch ligand transfectants are not immunogenic and can inhibit the
response to a challenge with antigen in a PLN assay. (a) PBS, H-2b
LNCs, Ab, or Ab/Dl1 cells were injected into the LFP of C3H/HeJ mice.
After 14 days, animals were challenged in the LFP with irradiated allo-
geneic LNCs (H-2b, from C57BL/10), Ab, or Ab/Dl1 cells, and after an
additional 7 days, PLNs from both sides were harvested, weighed, and
the results expressed as a ratio of weight (LPLN/RPLN). (b) A mixed
population of either Kb + Ab or Kb/Dl1 + Ab/Dl1 was used as the first
injection, and a second challenge with H-2b LNCs was given as above.
PLNs were harvested and data expressed as indicated above. (c)
Mixed populations of cells or PBS were given as a first injection as
shown. Animals were challenged with H-2b or H-2d (third
party–derived) LNCs. PLNs were harvested and data expressed as indi-
cated above. (d) Either Kb + Ab or Kb/Dl1 + Ab/Dl1 were given as a first
injection. DCs were used to test responsiveness to directly (direct,
C57BL/10 DCs) or indirectly (indirect, C3H/HeJ DCs fed with
C57BL/10 DCs) presented antigen. To check that the feeding proto-
col did not alter the function of DCs, control injections were with
C57BL/10 DCs fed with C57BL/10 DCs (direct control) and C3H/HeJ
DCs fed with C3H/HeJ DCs (syn control). Syn, syngeneic. n = 3–4 in
all groups; experiments are representative of at least three repeats.
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Ab/Dl1 did not show this early accumulation of cells
(e.g., P < 0.002 Kb plus Ab–pretreated versus Kb/Dl1 plus
Ab/Dl1–pretreated animals at 18 hours), although
there was some elevation in cell numbers between 48
and 72 hours. This elevation rapidly declined thereafter
and remained low until the end of the experiment.
Annexin V staining indicated that apoptosis in T cells
could not account for the early difference in cell num-
bers observed between Kb plus Ab–pretreated and
Kb/Dl1 plus Ab/Dl1–pretreated animals (Figure 4c),
and indeed there was a clearly reduced level of apopto-
sis in the T cells of the latter animals at the 48-hour
time point (P < 0.05 Kb plus Ab versus Kb/Dl1 plus
Ab/Dl1). This is consistent with previous reports indi-
cating that Notch can protect T cells from apoptosis
(5). It therefore appears that preconditioning with Dl1
transfectants affects early accumulation, proliferation,
and/or retention, but not death of cells at the site of
antigen challenge. At later time points in the assay,
however, apoptosis increased in T cells from animals
with all pretreatment regimens, but particularly in
those pretreated with either PBS or Kb/Dl1 plus
Ab/Dl1. The reasons for this were not investigated, but
because it was observed in both PBS-pretreated and
Kb/Dl1 plus Ab/Dl1–pretreated animals we concluded
that this was not of direct importance to the regulatory
effects induced by the Kb/Dl1 plus Ab/Dl1 cells.
Pretreatment with Dl1 transfectants can inhibit graft rejec-
tion in an antigen-specific fashion. We next tested the abil-
ity of the Notch ligand transfectants to inhibit graft
rejection using the mouse, fully vascularized, hetero-
topic heart transplant model (C57BL/10,H-2b>C3H/
HeJ,H-2k). In this strain combination, H-2Kb– and 
H-2Ab–expressing L cells delivered intravenously before
transplantation have been shown previously to mod-
estly enhance graft survival (20). As with PLN experi-
ments, pretreatment of recipients with either Kb/Dl1 or
Ab/Dl1 alone failed to effectively inhibit the response to
a challenge with H-2b, in this case in the form of a heart
allograft (Figure 5a). When we compared animals pre-
treated with mixtures of Kb plus Ab or Kb/Dl1 plus
Ab/Dl1, however, expression of the Notch ligand on
donor MHC-expressing cells considerably enhanced their
ability to prolong graft survival (Figure 5a, P < 0.05). This
effect was antigen specific because third-party (H-2d)
grafts were rejected with normal kinetics (Figure 5a).
Inhibition of allogeneic responses by delivery of
alloantigen in the context of Dl1 was seen in both the
PLN and the transplant experiments, despite a differ-
ence in the route of administration (subcutaneous ver-
sus intravenous), yet the inhibitory effect of the Kb and
Ab cells was observed only after intravenous delivery. To
further investigate if ligation of Notch could provide
an overriding inhibitory signal even when antigen is
delivered by a normally sensitizing route, recipient mice
were pretreated with mixtures of either Kb plus Ab or
Kb/Dl1 plus Ab/Dl1 cells intraperitoneally before
receiving an allograft. This route of pretreatment com-
pletely negated the modest beneficial effect seen with
Kb plus Ab pretreatment, while the prolongation of allo-
graft survival remained intact in animals that received
Kb/Dl1 plus Ab/Dl1 cells (Figure 5b).
Inhibition of rejection is dependent on a CD8+ cell popula-
tion. We next tested the possibility that an inhibitory
population of cells was involved in the Notch lig-
and–induced effects by depleting CD4+ or CD8+ cells
at the time of transplantation. Consistent with previ-
ous findings (29), depletion of CD4+ cells further
enhanced graft survival in animals pretreated with
either Kb plus Ab or Kb/Dl1 plus Ab/Dl1 cells (Figure
6a). Because CD4+ T cells are known to be critical in
the rejection of fully MHC-incompatible mouse heart
allografts, this was perhaps not surprising (29). Deple-
tion of CD8+ cells completely abrogated the beneficial
effects of pretreatment with the Kb/Dl1 plus Ab/Dl1
cells, however, even though CD8+ cells can be involved
as effector cells in the rejection of heart allografts (29)
Figure 4
Kinetics of cell accumulation and apoptosis in PLN assay. C3H/HeJ
mice were first injected with PBS, mixtures of Kb + Ab, or mixtures of
Kb/Dl1 + Ab/Dl1 in the LFPs, as in Figure 1. After 14 days, they were
challenged with irradiated allogeneic LNCs of H-2b origin. At various
time points after the second injection, PLNs were harvested for analy-
sis of cell numbers (a) expressed as the ratio of mean cell numbers
(LPLN/RPLN ± SEM) (b) expressed as ratio of mean T cell numbers
(LPLN/RPLN ± SEM), and (c) annexin V staining. Data are expressed as
the percentage of CD3+ cells coexpressing annexin V. Results of two sep-
arate experiments are pooled such that n = 3–6 animals per time point.
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(Figure 6a). These findings implicate a CD8+ cell in the
beneficial Notch ligand–induced effects observed.
Notch ligation of CD8+ cells alters their cytokine expression
potential. We were interested in the possibility that liga-
tion of Notch on T cells might alter their cytokine-
expression pattern. In preliminary experiments we
observed that the production of IFN-γ by T cells was
reduced significantly upon incubation with Kb/Dl1 plus
Ab/Dl1 cells in comparison to incubation with Kb plus
Ab cells (data not shown). Under these culture condi-
tions, however, the secretion of other
cytokines was very low. Use of the Dl1-Fc
fusion protein described above allowed us to
further explore the effects of Notch ligation
on isolated populations of cells in culture
under conditions where many different
cytokines could be produced. Indeed, we
have shown recently that Notch ligation in
CD4+ cells by Dl1-Fc induces a selective
enhancement of IL-10 production following TCR-medi-
ated activation (23). As demonstrated (Figure 6b) using
splenic CD8+ cells, ligation of Notch in the presence of T
cell receptor and costimulatory signals also has pro-
found effects on the type of cytokine produced, dramat-
ically decreasing the level of IFN-γ while increasing over
threefold the amount of IL-10 produced. Levels of IL-2
were also decreased and those of IL-13 were unaffected,
suggesting that Notch signaling inhibits differentiation
down a T1 pathway in these experiments.
Discussion
We have shown, we believe for the first time, that pre-
treatment with cells expressing a ligand of the Delta-
like family together with alloantigen is able to inhibit
the response to subsequent exposure to the same anti-
gen in an antigen-specific fashion. In the context of
organ transplantation this resulted in the prolongation
Figure 5
Notch ligand transfectants induce prolonged graft survival. (a)
C3H/HeJ recipients (H-2k) were injected intravenously with either
untransfected L cells (H-2k), Kb, Ab, Kb/Dl1, Ab/Dl1, a mixed popu-
lation of Kb + Ab, or a mixed population of Kb/Dl1 + Ab/Dl1. The dose
of Kb-expressing cells was 5 × 106, and the dose of Ab-expressing cells
was 106. These animals received heart allografts of H-2b origin 14
days later. To test antigen specificity of graft-survival prolongation,
one group that had been pretreated with Kb/Dl1 and Ab/Dl1 received
third-party grafts of BALB/c origin (H-2d). (b) C3H/He mice were
pretreated as above intraperitoneally (i.p.) or intravenously. Data for
intravenous injections are from the same animals in both a and b and
shown in both for comparative purposes. Heart grafts were assessed
daily by palpation for rejection. n = 4–6 in all groups.
Figure 6
CD8+ cell depletion reverses Dl1 enhancement of graft
survival, and purified CD8+ splenic cells make altered
cytokine responses upon ligation with Dl1. (a) Animals
were pretreated with Kb + Ab or Kb/Dl1 + Ab/Dl1 as in
Figure 5. All cell injections were given intraperitoneally.
One day before and on the day of transplantation ani-
mals received 1 mg CD8-depleting (YTS169) or CD4-
depleting (YTS 191) Ab intraperitoneally. Graft survival
was monitored by palpation, n = 4–6/group. (b) Puri-
fied splenic CD8+ cells were cocultured with immobi-
lized anti-CD3 (0.04 µg/ml), soluble anti-CD28, and
immobilized Dl1-Fc or IgG-4 control protein at the con-
centrations shown. Supernatants were harvested after
5 days and tested in ELISA for cytokines as shown. One
representative experiment of three is shown.
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of graft survival under conditions in which pretreat-
ment with alloantigen alone had no beneficial effect.
Mechanistically, this inhibition was shown to be
dependent upon the presence of CD8+ cells and did not
associate with increased apoptosis in responding cells.
Although engraftment was not permanent, we provid-
ed evidence that this was due to the fact that our pre-
treatment regimen did not target the indirect pathway
of presentation. Cell culture experiments indicated that
ligation of Notch on CD8+ responder cells was able to
alter their cytokine expression potential, diverting
them away from a T1-type response while enhancing
their ability to express IL-10.
Whether the different mammalian ligand families,
Jagged and Delta-like, signal for the same outcome in
mature lymphocytes is not known. There is evidence
from the developing hematopoietic system that these
ligands do not have completely redundant activities,
with Dl1 being able to completely inhibit B cell differ-
entiation whereas Jagged1 has no effect. Furthermore,
there is evidence that their signaling potential is modu-
lated differentially by proteins such as fringe (2, 30). Pre-
viously, we performed experiments in which DCs
expressing human Jagged1 and pulsed with peptide
were able to inhibit responses to the soluble protein Der
p 1 (17) and showed that the inhibition was mediated
by a CD4+ population of cells. In those studies CD8+
cells capable of inhibiting responses in adoptive trans-
fer experiments were not generated, but this may well be
a function of the antigen used, rather than an inherent
difference in the ability of the two different Notch lig-
ands used to affect different populations of cells. Exper-
iments are in progress to further compare the effects of
signaling through the two families of ligands on the
peripheral immune system.
The lack of an effect of the Dl1-expressing L cells on
T cell responses to indirectly presented antigen could
be due to the fact that Notch ligand on APCs is cis- and
not trans-acting, or it may be that in the PLN, T cells
with specificity for indirectly presented alloantigen
would not come sufficiently close to the Dl1-transfect-
ed L cells to be affected by the presence of Notch ligand.
Alternatively, it could be that inherent differences in
the requirements for stimulation by direct and indirect
pathways as suggested by others (31) affects the unre-
sponsiveness induced by Notch ligation. These issues,
and in particular whether Notch ligand on APCs is
either cis- or trans-acting in this system are currently
under investigation.
Despite the significant prolongation observed in trans-
plants of all animals pretreated with Kb/Dl1 plus Ab/Dl1
cells, all animals eventually rejected their grafts. This was
perhaps not surprising in view of the fact that our pre-
treatment regimen targeted only the direct pathway of
antigen presentation, and it is clear from the work of
others that indirect presentation can result in rapid graft
rejection (26–28). We presented evidence that an
inhibitory CD8+ cell is responsible for the prolonged
graft survival observed since depletion of this population
at the time of grafting, a strategy used previously by oth-
ers to demonstrate a similar phenomenon (32), com-
pletely abrogated the beneficial effects of the pretreat-
ment protocol. There are many reports of CD8+
suppressor/inhibitory cells that operate through a vari-
ety of cell contact–dependent and independent mecha-
nisms (33–39). In the work of others, CD8+ regulatory
cells have been documented recently both in patients
with antigen-specific unresponsiveness to influenza
matrix peptide (40) and after culture of human T cells
with CD40 ligand–activated plasmacytoid DCs (41). In
the latter study the regulatory cells were shown to pro-
duce elevated levels of IL-10, but reduced levels of all
other cytokines tested compared with CD8+ effector cells
activated by monocyte-derived DCs. Our data provide
further evidence implicating the activity of CD8+ cells in
antigen-specific unresponsiveness in vivo, although our
data do not define the cell lineage involved.
Our data do not exclude the possibility that a CD4+
cell is also involved in the beneficial effects of Notch
ligand–transfected cells. Indeed, the requirement for
the inclusion of MHC class II–expressing transfectants
in the pretreatment protocol, taken together with our
previous data (17), argues strongly in favor of the
involvement of CD4+, MHC class II–reactive cells in col-
laboration with the CD8+ cells. There are many reports
of CD4+ regulatory cells with a variety of phenotypic
and functional characteristics (42–48), and it will be of
interest to examine whether any of these cells are
induced or expanded in the present system. Such cells,
which include the naturally occurring CD4+CD25+ reg-
ulatory cells (44, 45) and those induced or expanded by
experimental manipulation (42, 48–52), have been
reported variably to depend upon cytokines, including
IL-10, for their induction and/or function. The rela-
tionship between naturally occurring regulatory cells
and those induced or expanded by experimental
manipulation is poorly defined, but it is apparent for
at least one cell type (i.e., IL-10–producing Tr1 cells)
that they have different origins (53). The eventual loss
of grafts in our experiments could be explained by the
loss of the CD8+ (and putative CD4+) inhibitory popu-
lations since the activating signal for them (i.e., APCs
of graft origin) is lost rapidly from the graft (54), and it
is clear in other models of transplantation that inhibi-
tion or tolerance can be maintained only in the contin-
ued presence of antigen (55).
Epitope spreading, in which tolerance induced to one
peptide of an antigen extends to the entire protein, is a
common feature of many experimental models of tol-
erance. Similarly, in other experimental transplanta-
tion models, long-term engraftment or tolerance may
be achieved with preoperative treatment regimens that
include only single-donor alloantigens, suggesting that
in these experiments spreading of tolerance can not
only account for unresponsiveness to haplotypes rec-
ognized directly, but also to alloantigen recognized
indirectly (56). Indeed, it is becoming clear that in long-
term surviving recipients of allogeneic grafts, it is the
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CD4+ T cells that recognize antigen indirectly that
maintain the tolerant state (57, 58). These and other
transplantation tolerance studies have in common a
phase of nonspecific immunosuppression during the
induction of unresponsiveness that will target all T
cells whether they recognize alloantigen directly or
indirectly. This is not the case in our experiments, and
it is likely that nonspecific immunosuppression will
result in the ablation and/or inactivation of T cells rec-
ognizing alloantigen directly and indirectly, allowing
the emergence of a dominant population of regulatory
cells. Since in long-term surviving grafts the primary
stimulus will be to regulatory T cells recognizing
alloantigen indirectly, it is not surprising that this pop-
ulation is maintained in such experiments. It has been
difficult to raise inhibitory cells that regulate respons-
es to directly presented alloantigen (31), but our data
establish that this may indeed be possible.
Our understanding, as derived from developmental sys-
tems, indicates that the Notch-signaling pathway con-
trols cell fate choices through influencing proliferation,
differentiation, and death (1). While Notch may itself
direct cell fate, more usually it acts by inhibiting differ-
entiation along one pathway, thereby allowing the cell to
be influenced by other cell extrinsic or intrinsic cues to
differentiate down an alternate pathway. The data pre-
sented in this paper is consistent with the hypothesis that
Notch signaling in mature CD8+ lymphocytes inhibits
differentiation along a T1 program, thereby allowing
them to mature into a T2/inhibitory population. The
integration of Notch signaling with T cell receptor and
costimulatory and cytokine-mediated signaling is obvi-
ously critical to the outcome of this process and the sub-
ject of further investigation in our laboratories.
We have demonstrated that delivery of cells coexpress-
ing antigen and a Notch ligand of the Delta-like family
can subvert, in an antigen-specific fashion, the normal-
ly powerful immune response to alloantigen, even when
that antigen is delivered by a route that would otherwise
be sensitizing. This inhibition is dependent on the pres-
ence of CD8+ cells at the time of antigen challenge. We
have shown that animals pretreated with Dl1-expressing
cells showed a very early inhibition of cell accumulation
at the site of antigen challenge and that direct ligation of
the Notch receptor on splenic CD8+ cells enhances the
production of IL-10 while dramatically reducing the pro-
duction of IFN-γ. These latter data suggest that Notch
signaling can inhibit differentiation of mature CD8+
cells down a T1 pathway.
The ability to induce antigen-specific unresponsive-
ness without concomitant nonspecific immunosup-
pression is highly desirable and should not only be ben-
eficial in the context of bone marrow and organ
transplantation, but also in the context of diseases of
autoimmune or allergic pathology.
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